MSFrontier

Results pending

Immune reconstitution (cladribine, alemtuzumab, aHSCT): reduce relapses and new lesions in relapsing MS

Trial timeline

Phase 320052007

Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.

relapsing MS · Immune reconstitution (cladribine, alemtuzumab, aHSCT)

Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.

Trials
18
Running now
0
Controlled phase 2/3 trials
5
People in controlled trials
4371

Deciding trials (phase 3): 3 met, 0 did not.

Other linked trials: 15

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • CARE-MS IIdecides the statusMet main goal

    Phase 3 · 2007 · Compared with interferon beta-1a · MSFT-NCT00548405

  • CARE-MS Idecides the statusMet main goal

    Phase 3 · 2007 · Compared with interferon beta-1a · MSFT-NCT00530348

  • Oral Cladribine versus Placebo in RRMSdecides the statusResult in a paper, not read yet

    Phase 3 · 2005 · Placebo-controlled · MSFT-2004-005148-28

  • CLARITYdecides the statusMet main goal

    Phase 3 · 2005 · Placebo-controlled · MSFT-NCT00213135

Other linked trials: 15

These linked trials do not set the status.

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-27First listed as Results pending

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error